Brief introduction:The first beta blocker which completed the Quality Consistency Evaluationpassed in China. Indicated to lower high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Brief introduction:It is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days.
Brief introduction:Deemed to have completed the Quality Consistency Evaluation; It's used for treatment of following: prevent Atherothrombosis; patients with acute myocardial infarction(AMI), ischemic stroke, peripheral arterial disease(PAD) and acute coronary syndrome(ACS).
Tel +86-28-87827187; E-mail: sales@eastonpharma.cn
API business
Factory: Sichuan Qingmu Pharmaceutical Co., Ltd
Add: No.55, South Shunjiang Avenue, East Economic Development Zone, Meishan City, Sichuan, 612100, China
Sales/Marketing/BD/CDMO: Tel +86-28-87827187;
E-mail: sales@eastonpharma.cn
Human Resources
Headquarter: No.8, Ankang Road, Tianfu International Bio-town, Shuangliu District, Chengdu, 610200, China
Hi-tech factory: No.8, Xiyuan Ave., Hi-tech District, Chengdu, 611731, China
Email: hr@eastonpharma.cn
This website does not publish the product information of narcotic drugs, psychotropic drugs, toxic drugs for medical use, radioactive drugs, drug rehabilitation drugs and preparations of medical institutions.|
Copyright ? 成都苑東生物制藥股份有限公司 ALL Rights Reserved互聯(lián)網(wǎng)藥品信息服務(wù)資格證編號(hào):(川)-非經(jīng)營(yíng)性-2021-0036